title: The University of California at Los Angeles experience in heart transplantation.
abstract: In the last decade, the number of patients undergoing heart transplantation has steadily increased as a result of expanding indications for cardiac transplantation. The limitation on the number of transplants performed has been the number of donor organs available. At UCLA, 511 heart transplant procedures were performed from 1984-1994. The mean number of rejection episodes and infections per patient in the first year after transplant was 1.1+/-1.3 and 1.0+/-1.2, respectively. Actuarial one-, 3-, and 5-year survival rates were 84%, 77% and 73%, respectively. Survival of patients age 60 years and over (n=105) was comparable to that of patients under age 60. Despite transplanting more critically ill patients (Status 1) and having longer cold ischemic times, outcomes have been improving. We have been pursuing corticosteroid-free immunosuppression, which no doubt has led to the decrease in infection complications. Furthermore, our work with pravastatin early after transplantation has led to a decrease in clinically severe rejection episodes which has translated into improved survival. Pravastatin also appeared to decrease the development of transplant coronary artery disease and appeared to have an adjunct immunosuppressive effect in our heart transplant patients on CsA-based immunosuppression. Future studies will include the use of mycophenolate mofetil which has properties against B-lymphocytes in addition to T-lymphocytes to block both humoral and cellular rejection. Our program continues to seek better ways to improve survival and the quality of life of our patient population.
authors.affiliation: Divisions of Cardiothoracic Surgery and Cardiology, UCLA School of Medicine, Los Angeles, California, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Kobashigawa
authors.forename: H
authors.initials: H
authors.lastname: Laks
authors.forename: D C
authors.initials: DC
authors.lastname: Drinkwater
authors.forename: M A
authors.initials: MA
authors.lastname: Hamilton
authors.forename: J D
authors.initials: JD
authors.lastname: Moriguchi
authors.forename: G
authors.initials: G
authors.lastname: Fonarow
authors.forename: A
authors.initials: A
authors.lastname: Blitz
authors.forename: A
authors.initials: A
authors.lastname: Hage
authors.forename: N
authors.initials: N
authors.lastname: Kawata
mesh_terms: D000046:Academic Medical Centers; D000293:Adolescent; D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003327:Coronary Disease / Q000209:etiology; D005260:Female; D006084:Graft Rejection; D016027:Heart Transplantation / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007223:Infant; D007231:Infant, Newborn; D007239:Infections / Q000209:etiology; D015141:Los Angeles; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D017035:Pravastatin / Q000627:therapeutic use; D015996:Survival Rate; D014019:Tissue Donors
chemical_list: D000924:Anticholesteremic Agents; D017035:Pravastatin